Profil
Pablo Umaña is the founder of Roche Glycart AG, which was founded in 2000.
He held the title of Research Director at the time of founding.
Additionally, he worked as Head-Cancer Immunotherapy Discovery at Roche Holding AG in a former position.
Postes actifs de Pablo Umaña
| Sociétés | Poste | Début |
|---|---|---|
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Founder | 01/09/2000 |
Anciens postes connus de Pablo Umaña
| Sociétés | Poste | Fin |
|---|---|---|
| ROCHE HOLDING AG | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| Entreprise privées | 1 |
|---|---|
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
